These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2308980)

  • 1. Efficacy of bone marrow purging in AML using monoclonal antibodies and complement.
    Mills LE; Ball ED; Howell AL; Cornwell GG; Thompson L; Spruce W; Miller WE; McMillan R
    Prog Clin Biol Res; 1990; 333():165-70. PubMed ID: 2308980
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
    Ball ED; Vredenburgh JJ; Mills LE; Cornwell GG; Schwarz L; Howell AL; Troy K
    Bone Marrow Transplant; 1990 Oct; 6(4):277-80. PubMed ID: 1982228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vim-2, candidate monoclonal antibody for purging autologous marrow grafts in acute myeloblastic leukaemia.
    Delwel R; Bot F; Knapp W; Löwenberg B
    Bone Marrow Transplant; 1987 Aug; 2(2):149-54. PubMed ID: 3332163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibody and purging].
    Ueda R; Morishima Y
    Gan No Rinsho; 1989 May; Spec No():294-302. PubMed ID: 2601016
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibody 55 (CD10) and complement used for purging autologous bone marrow in common acute lymphoblastic leukemia.
    Bai Y; Piao XH; Luo QL; Mao BZ
    Chin Med J (Engl); 1990 May; 103(5):385-90. PubMed ID: 2118055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia.
    Robertson MJ; Roy DC; Stone RM; Ritz J
    Prog Clin Biol Res; 1994; 389():47-63. PubMed ID: 7700916
    [No Abstract]   [Full Text] [Related]  

  • 7. Applicability of antimyeloid monoclonal antibodies (L4F3, 1G10) to autologous bone marrow transplantation for patients with acute myelogenous leukemia.
    Takahashi M; Maruyama S; Moriyama Y; Shibata A
    Transplant Proc; 1992 Feb; 24(1):416-8. PubMed ID: 1539334
    [No Abstract]   [Full Text] [Related]  

  • 8. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
    Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J
    Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies.
    Ball ED
    Bone Marrow Transplant; 1988 Sep; 3(5):387-92. PubMed ID: 3056546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone-marrow purging with monoclonal antibodies and human complement in ALL and AML.
    Majdic O; Sugita K; Touw I; Köller U; Stockinger H; Delwel R; Löwenberg B; Knapp W
    Haematol Blood Transfus; 1987; 31():86-8. PubMed ID: 3327791
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of immunorosettes for purging of bone marrow in childhood cancer.
    Slaper-Cortenbach IC; Wijngaarden-du Bois MJ; Admiraal LG; Tetteroo PA; Figdor CG; van Leeuwen EF
    Prog Clin Biol Res; 1990; 333():337-44. PubMed ID: 2308990
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
    Vallera DA; Uckun FM
    Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bone marrow transplantation in the treatment of acute leukemias].
    Moiseev SI; Ganapiev AA; Abdulkadyrov KM
    Ter Arkh; 1996; 68(12):8-10. PubMed ID: 9054052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous bone marrow transplantation for haematological malignancies--experiences of the centre of Zagreb.
    Nemet D; Labar B; Bogdanic V; Skodlar J; Petrovecki M; Mrsic M; Maravic N; Sneller V; Radman I; Kovacevic-Metelko J
    Wien Med Wochenschr; 1995; 145(2-3):61-4. PubMed ID: 7762256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of complement by an automated cell processor enhances cytotoxicity of monoclonal antibody sensitized leukemia cells.
    Howell AL; Fogg-Leach M; Davis BH; Ball ED
    Bone Marrow Transplant; 1989 May; 4(3):317-22. PubMed ID: 2659117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
    Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Indications for allogeneic bone marrow transplantation (BMT) in adult acute myelogenous leukemia: matched-pair analysis in comparison with chemotherapy in patients achieving initial remission].
    Sakura T
    Rinsho Ketsueki; 2001 May; 42(5):380-4. PubMed ID: 11452455
    [No Abstract]   [Full Text] [Related]  

  • 20. [In vitro treatment of human bone marrow in the elimination of tumor cells: initial experiences with cytotoxic monoclonal anti-T-cell antibody LAU-A1].
    Brun del Re GP; Baumgartner C; Stern AC; Hirt A; Carrel S
    Schweiz Med Wochenschr; 1984 Oct; 114(40):1379-82. PubMed ID: 6333721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.